Novartis has raised its FY23 outlook, expecting its Innovative Medicines sales to grow in the high single digits, up from the previous mid-single digit growth forecast. The company also anticipates its core operating income to grow in the low double digits to mid-teens, an increase from the previous high single to low double digit growth prediction. This revised outlook is due to strong H1 momentum.